Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EBIT: 2016-2025

Historic EBIT for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $29.4 million.

  • Tg Therapeutics' EBIT rose 136.17% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 20452.28%. This contributed to the annual value of $41.9 million for FY2024, which is 103.21% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' EBIT is $29.4 million, which was down 15.72% from $34.8 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' EBIT ranged from a high of $114.8 million in Q3 2023 and a low of -$92.9 million during Q4 2021.
  • Moreover, its 3-year median value for EBIT was $8.8 million (2024), whereas its average is $12.3 million.
  • In the last 5 years, Tg Therapeutics' EBIT skyrocketed by 428.30% in 2023 and then tumbled by 89.17% in 2024.
  • Quarterly analysis of 5 years shows Tg Therapeutics' EBIT stood at -$92.9 million in 2021, then grew by 16.58% to -$77.5 million in 2022, then skyrocketed by 83.90% to -$12.5 million in 2023, then spiked by 339.88% to $29.9 million in 2024, then surged by 136.17% to $29.4 million in 2025.
  • Its EBIT stands at $29.4 million for Q3 2025, versus $34.8 million for Q2 2025 and $8.6 million for Q1 2025.